Efficacy and dose response of Lactiplantibacillus plantarum in diarrhea-predominant irritable bowel syndrome

doi:10.3748/wjg.v29.i28.4451

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 28

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9082)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

219

WORD

HTML

5607

Figures (1-3)

479

Tables (1-3)

453

Sum=6810

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

211

Download

735

Sum=946

Publishing Process of This Article

Item

Count

Browse

188

Download

725

Sum=913

Jul 28, 2023 (publication date) through Feb 11, 2025

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastroenterol. Jul 28, 2023; 29(28): 4451-4465
Published online Jul 28, 2023. doi: 10.3748/wjg.v29.i28.4451

Table 2 Irritable bowel syndrome symptom severity total and domain-specific scores over the intervention period

	Placebo (n = 104)	L. plantarum 1B (n = 104)		L. plantarum 10B (n = 99)
	mean (SD)	mean (SD)	P vs Placebo¹	mean (SD)	P vs Placebo¹	P vs 1B dose²
IBS-SSS total score
Day 0	308.70 (70.91)	315.95 (62.07)		302.85 (61.06)
AbsΔ (Day 28)	-35.68 (60.81)	-66.37 (72.27)	0.0098	-85.80 (89.53)	< 0.0001	0.0956
AbsΔ (Day 56)	-58.82 (74.75)	-128.45 (83.30)	< 0.0001	-156.77 (99.06)	< 0.0001	0.0298
Abdominal pain severity
Day 0	67.05 (17.11)	68.80 (13.40)		67.07 (13.77)
AbsΔ (Day 28)	-9.24 (19.67)	-15.45 (18.36)	0.0830	-20.76 (22.76)	< 0.0001	0.0736
AbsΔ (Day 56)	-14.38 (21.18)	-28.91 (20.36)	< 0.0001	-36.52 (24.39)	< 0.0001	0.0176
Abdominal pain duration
Day 0	41.11 (14.13)	42.60 (14.55)		39.37 (13.75)
AbsΔ (Day 28)	-5.35 (13.50)	-8.46 (12.05)	0.1975	-7.89 (12.62)	0.0484	0.7463
AbsΔ (Day 56)	-8.38 (13.75)	-15.29 (13.72)	0.0006	-19.68 (14.91)	< 0.0001	0.0315
Abdominal distension
Day 0	65.08 (18.11)	66.31 (15.11)		63.07 (14.34)
AbsΔ (Day 28)	-8.66 (18.19)	-14.69 (17.68)	0.0600	-18.55 (22.62)	< 0.0001	0.1849
AbsΔ (Day 56)	-14.00 (20.76)	-29.33 (21.64)	< 0.0001	-35.45 (24.00)	< 0.0001	0.0598
Bowel habits
Day 0	68.32 (15.64)	69.35 (13.70)		66.72 (14.55)
AbsΔ (Day 28)	-6.45 (12.02)	-14.36 (18.66)	0.0020	-19.52 (21.48)	< 0.0001	0.0714
AbsΔ (Day 56)	-11.19 (16.63)	-27.73 (19.54)	< 0.0001	-32.31 (25.12)	< 0.0001	0.1561
Effect on quality of life
Day 0	67.13 (15.85)	68.90 (14.47)		66.62 (12.85)
AbsΔ (Day 28)	-5.97 (12.03)	-13.40 (17.48)	0.0060	-19.08 (21.13)	< 0.0001	0.0395
AbsΔ (Day 56)	-10.86 (15.74)	-27.19 (19.19)	< 0.0001	-32.81 (23.66)	< 0.0001	0.0690

¹ANCOVA using Dunnett’s test adjustment with treatment as factor and baseline as covariate vs placebo.

²Two-sample t-test comparing dose groups.

IBS-SSS: Irritable bowel syndrome-severity scoring system; AbsΔ: Absolute change; L. plantarum: Lactiplantibacillus plantarum.

Citation: Martoni CJ, Srivastava S, Damholt A, Leyer GJ. Efficacy and dose response of Lactiplantibacillus plantarum in diarrhea-predominant irritable bowel syndrome. World J Gastroenterol 2023; 29(28): 4451-4465
URL: https://www.wjgnet.com/1007-9327/full/v29/i28/4451.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i28.4451